{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:04:03Z","timestamp":1761491043340,"version":"build-2065373602"},"reference-count":35,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:00:00Z","timestamp":1717459200000},"content-version":"vor","delay-in-days":64,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["AG064803","P30AG072958"],"award-info":[{"award-number":["AG064803","P30AG072958"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["alz-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["A&amp;amp;D Transl Res &amp;amp; Clin Interv"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>INTRODUCTION<\/jats:title>\n                    <jats:p>Alzheimer's disease (AD) is a neurodegenerative disorder characterized by declines in cognitive and functional severities. This research utilized the Clinical Dementia Rating (CDR) to assess the influence of tilavonemab on these deteriorations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>Longitudinal Item Response Theory (IRT) models were employed to analyze CDR domains in early\u2010stage AD patients. Both unidimensional and multidimensional models were contrasted to elucidate the trajectories of cognitive and functional severities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>We observed significant temporal increases in both cognitive and functional severities, with the cognitive severity deteriorating at a quicker rate. Tilavonemab did not demonstrate a statistically significant effect on the progression in either severity. Furthermore, a significant positive association was identified between the baselines and progression rates of both severities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DISCUSSION<\/jats:title>\n                    <jats:p>While tilavonemab failed to mitigate impairment progression, our multidimensional IRT analysis illuminated the interconnected progression of cognitive and functional declines in AD, suggesting a comprehensive perspective on disease trajectories.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Highlights<\/jats:title>\n                    <jats:p>\n                      <jats:list>\n                        <jats:list-item>\n                          <jats:p>Utilized longitudinal Item Response Theory (IRT) models to analyze the Clinical Dementia Rating (CDR) domains in early\u2010stage Alzheimer's disease (AD) patients, comparing unidimensional and multidimensional models.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Observed significant temporal increases in both cognitive and functional severities, with cognitive severity deteriorating at a faster rate, while tilavonemab showed no statistically significant effect on either domain's progression.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Found a significant positive association between the baseline severities and their progression rates, indicating interconnected progression patterns of cognitive and functional declines in AD.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Introduced the application of multidimensional longitudinal IRT models to provide a comprehensive perspective on the trajectories of cognitive and functional severities in early AD, suggesting new avenues for future research including the inclusion of time\u2010dependent random effects and data\u2010driven IRT models.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/trc2.12471","type":"journal-article","created":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T05:23:46Z","timestamp":1717478626000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Assessing tilavonemab efficacy in early Alzheimer's disease via longitudinal item response theory modeling"],"prefix":"10.1002","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3950-1980","authenticated-orcid":false,"given":"Xiaoxiao","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Biostatistics &amp; Bioinformatics Duke University  Durham North Carolina USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haotian","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Biostatistics &amp; Bioinformatics Duke University  Durham North Carolina USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael W.","family":"Lutz","sequence":"additional","affiliation":[{"name":"Division of Translational Brain Sciences Department of Neurology Duke University Medical Center  Durham North Carolina USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantin","family":"Arbeev","sequence":"additional","affiliation":[{"name":"Social Science Research Institute Duke University  Durham North Carolina USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor","family":"Akushevich","sequence":"additional","affiliation":[{"name":"Social Science Research Institute Duke University  Durham North Carolina USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anatoli","family":"Yashin","sequence":"additional","affiliation":[{"name":"Social Science Research Institute Duke University  Durham North Carolina USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen A.","family":"Welsh\u2010Bohmer","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Duke University  Durham North Carolina USA"},{"name":"Duke Clinical Research Institute (DCRI) Duke University Durham North Carolina USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4214-5809","authenticated-orcid":false,"given":"Sheng","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Biostatistics &amp; Bioinformatics Duke University  Durham North Carolina USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,6,4]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32205-4"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.11.2412-a"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1159\/000341731"},{"key":"e_1_2_8_5_1","unstructured":"Health UDo Services H.Guidelines for Industry Alzheimer's Disease: Developing Drugs for the Treatment of Early Stage Disease.2013."},{"key":"e_1_2_8_6_1","unstructured":"Health UDo Services H.Early Alzheimer's Disease: Developing Drugs For Treatment Guidelines for Industry.2018."},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature19323"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awad024"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12773"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.068296"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12219"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-020-02605-3"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12210"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.7347"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1214\/17-AOAS1059"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.13311"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29154"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12853"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.13890"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-3462-1"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4419-0742-4"},{"key":"e_1_2_8_23_1","unstructured":"SD T.Stan modeling language. User's guide and reference manual.2021."},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-6941.2001.tb00841.x"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.05.2409"},{"key":"e_1_2_8_26_1","doi-asserted-by":"crossref","unstructured":"VermaN MarkeyMK.Item response analysis of Alzheimer's disease assessment scale.2014 36th Annual International Conference of the IEEE Engineering in Medicine and Biology Society.IEEE;2014:2476\u20102479.","DOI":"10.1109\/EMBC.2014.6944124"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/WAD.0b013e318265bcc1"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/ggi.13552"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/WAD.0b013e3182420bdf"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1041610211002298"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-014-1315-5"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12280"},{"key":"e_1_2_8_33_1","doi-asserted-by":"crossref","first-page":"212","DOI":"10.14283\/jpad.2023.13","article-title":"Longitudinal exposure\u2014response modeling of multiple indicators of Alzheimer's disease progression","volume":"10","author":"Polhamus D","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/00273171.2018.1496317"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26847"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27058"}],"container-title":["Alzheimer's &amp; Dementia: Translational Research &amp; Clinical Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/trc2.12471","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:56:06Z","timestamp":1761490566000},"score":1,"resource":{"primary":{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1002\/trc2.12471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1002\/trc2.12471"],"URL":"https:\/\/doi.org\/10.1002\/trc2.12471","archive":["Portico"],"relation":{},"ISSN":["2352-8737","2352-8737"],"issn-type":[{"type":"print","value":"2352-8737"},{"type":"electronic","value":"2352-8737"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"2023-11-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e12471"}}